OSLO (Thomson Financial) - Norwegian medical research group Algeta ASA said a leading US medical journal has published a paper showing the potential of its technology in treating cancer. Algeta said in a statement that a research paper has been published on its TH-1 cancer treatment technology in the medial journal Blood, the official journal of the American Society of Hematology. Algeta said the paper showed the potential of its technology for ‘targeted cancer therapy’.
